Evolus: Aesthetic Spending Bounceback (Ticker: EOLS)
Evolus posted 21% quarterly revenue growth as U.S. facial-injectable spending bottoms, while making progress toward GAAP profitability.
NASDAQ
Cap as of Nov 17 1 story
Get EOLS news in Claude, ChatGPT or your own code. See plans
Evolus posted 21% quarterly revenue growth as U.S. facial-injectable spending bottoms, while making progress toward GAAP profitability.